Michel Finance is appointed CEO.
Executive team is strengthened with the appointment of:
Daniele Zanotti (the former CEO) as Chief Technology and Innovation Officer leading technology developments and the execution of programs,
Professor François Laborde as Chief Clinical and Scientific Affairs Officer,
Marianna Luppi as Regulatory Affairs Director,
Brian Burg as Cardiovascular Program Director.
Return to the news page
